https://www.pharmaradar360.com/article/pressure-cooker-pilot-destroys-pfas-in-sewage-but-scaling-up-is-a-challenge-e31e555c4cc81f97PharmaRadar360en2026-09-16T16:32:07.000Z‘Pressure cooker’ pilot destroys PFAS in sewage, but scaling up is a challengehttps://www.pharmaradar360.com/article/the-sucker-s-dilemma-the-psychology-of-getting-conned-e818af4adb86d4fdPharmaRadar360en2026-09-16T16:31:20.000ZThe sucker’s dilemma: The psychology of getting connedhttps://www.pharmaradar360.com/article/mamdani-s-consumer-cop-brings-lina-khan-s-playbook-to-nyc-5101674923b0f52ePharmaRadar360en2026-09-16T16:30:11.000ZMamdani’s Consumer Cop Brings Lina Khan’s Playbook to NYChttps://www.pharmaradar360.com/article/how-do-you-know-if-the-beef-you-re-buying-is-from-the-usa-adcafe36f1d419d1PharmaRadar360en2026-09-16T16:27:43.000ZHow do you know if the beef you're buying is from the USA?https://www.pharmaradar360.com/article/farmers-face-significant-head-winds-this-fall-harvest-thanks-to-high-fuel-costs-a2e3ddf655702b09PharmaRadar360en2026-09-16T16:27:00.000ZFarmers face significant head winds this fall harvest thanks to high fuel costs and dryhttps://www.pharmaradar360.com/article/as-soybeans-near-harvest-rain-and-disease-questions-remain-16f415c0d0633923PharmaRadar360en2026-09-16T16:24:03.000ZAs soybeans near harvest, rain and disease questions remainhttps://www.pharmaradar360.com/article/sling-ropes-in-123m-for-oral-thyroid-eye-disease-drug-545cdd139d817376PharmaRadar360en2026-09-16T15:57:11.000ZSling ropes in $123m for oral thyroid eye disease drughttps://www.pharmaradar360.com/article/heart-recipient-honours-organ-donors-with-transplant-games-overture-91018807af22fe2fPharmaRadar360en2026-09-16T15:50:48.000ZHeart recipient honours organ donors with Transplant Games overturehttps://www.pharmaradar360.com/article/gilead-reaches-hiv-prep-agreements-hong-kong-investigates-cloudbreak-ipo-9f9b09cdff1fc0b2PharmaRadar360en2026-09-16T15:37:00.000ZGilead reaches HIV PrEP agreements; Hong Kong investigates Cloudbreak IPOhttps://www.pharmaradar360.com/article/sicadi-resultados-de-categorizacion-de-docentes-investigadores-as-de-la-unlp-e34068010678089cPharmaRadar360en2026-09-16T15:36:44.000ZSICADI – Resultados de Categorización de Docentes Investigadores/as de la UNLPhttps://www.pharmaradar360.com/article/raw-material-complexities-and-strategies-with-for-advanced-therapies-75982b30edb4c2d1PharmaRadar360en2026-09-16T15:33:47.000ZRaw Material Complexities and Strategies with for Advanced Therapieshttps://www.pharmaradar360.com/article/legionellosis-in-residents-of-england-and-wales-2025-ddbdab6f2a833e23PharmaRadar360en2026-09-16T15:33:27.000ZLegionellosis in residents of England and Wales: 2025https://www.pharmaradar360.com/article/nasa-hubble-fellowship-program-2027-803e4575d6d906d0PharmaRadar360en2026-09-16T15:25:40.000ZNASA Hubble Fellowship Program 2027https://www.pharmaradar360.com/article/from-counting-sheep-to-forty-winks-three-tips-to-get-your-kids-back-on-a-healthy-a507f783ecee492dPharmaRadar360en2026-09-16T15:25:00.000ZFrom counting sheep to forty winks: three tips to get your kids back on a healthy sleep schedulehttps://www.pharmaradar360.com/article/cooking-class-livestream-italian-ground-turkey-frittata-d84cf9acb61ad274PharmaRadar360en2026-09-16T15:09:15.000ZCooking Class Livestream: Italian Ground Turkey Frittatahttps://www.pharmaradar360.com/article/european-adrs-inched-up-as-telecom-and-biotech-led-472ac474aa915400PharmaRadar360en2026-09-16T15:08:41.000ZEuropean ADRs Inched Up As Telecom And Biotech Ledhttps://www.pharmaradar360.com/article/cold-mortality-monitoring-report-england-winter-2024-to-2025-6966878552215588PharmaRadar360en2026-09-16T15:00:05.000ZCold mortality monitoring report, England: winter 2024 to 2025https://www.pharmaradar360.com/article/kibow-biotech-wins-2026-webaward-for-best-science-website-52d6a8ecf05d157cPharmaRadar360en2026-09-16T15:00:00.000ZKibow® Biotech Wins 2026 WebAward for Best Science Websitehttps://www.pharmaradar360.com/article/mayer-brown-represents-underwriters-on-teva-pharmaceutical-s-us-4-9-billion-seni-3890078c3ce9091aPharmaRadar360en2026-09-16T14:58:53.000ZMayer Brown represents underwriters on Teva Pharmaceutical’s US$4.9 billion senior notes offeringhttps://www.pharmaradar360.com/article/glp-1s-what-is-behind-the-variation-in-efficacy-f2db9c17e19f1a25PharmaRadar360en2026-09-16T14:58:01.000ZGLP-1s: what is behind the variation in efficacy?https://www.pharmaradar360.com/article/bauchaortenaneurysma-nach-evar-neue-wege-zur-besseren-nachsorge-fad268c1acffb4b9PharmaRadar360en2026-09-16T14:57:05.000ZBauchaortenaneurysma nach EVAR – neue Wege zur besseren Nachsorgehttps://www.pharmaradar360.com/article/compras-y-contrataciones-ab71a6a5fe0835ecPharmaRadar360en2026-09-16T14:53:26.000ZCompras y Contratacioneshttps://www.pharmaradar360.com/article/drug-shortages-a426e4f99d62d81aPharmaRadar360en2026-09-16T14:50:19.000ZDrug Shortageshttps://www.pharmaradar360.com/article/law-firm-leader-to-chair-2026-long-island-heart-stroke-ball-ff797735c0b6f755PharmaRadar360en2026-09-16T14:47:00.000ZLaw firm leader to chair 2026 Long Island Heart & Stroke Ballhttps://www.pharmaradar360.com/article/vivre-avec-et-apres-un-cancer-les-promesses-et-les-defis-de-la-sante-numerique-945e8a65c5d7a4f3PharmaRadar360en2026-09-16T14:46:47.000ZVivre avec et après un cancer : les promesses et les défis de la santé numériquehttps://www.pharmaradar360.com/article/estates-safety-fund-initial-schemes-and-associated-funding-allocations-2026-to-2-578511fd55580096PharmaRadar360en2026-09-16T14:42:12.000ZEstates Safety Fund: initial schemes and associated funding allocations, 2026 to 2030https://www.pharmaradar360.com/article/novartis-ends-als-program-after-phase-2-flop-adding-to-r-d-woes-da0b1c01b0e1cfd3PharmaRadar360en2026-09-16T14:28:27.000ZNovartis ends ALS program after phase 2 flop, adding to R&D woeshttps://www.pharmaradar360.com/article/buy-european-incentivising-eu-based-pharmaceutical-manufacturing-f0be7ec5d4a13c8dPharmaRadar360en2026-09-16T14:23:57.000ZBuy European: Incentivising EU Based Pharmaceutical Manufacturinghttps://www.pharmaradar360.com/article/sling-therapeutics-announces-first-patients-dosed-in-global-phase-3-orbit-pivota-493b66e4547da753PharmaRadar360en2026-09-16T14:12:34.000ZSling Therapeutics Announces First Patients Dosed in Global Phase 3 ORBIT Pivotal Trial of Linsitinib for Thyroid Eye Diseasehttps://www.pharmaradar360.com/article/legend-biotech-names-novartis-veteran-ingrid-zhang-as-new-ceo-c36c83304cfb057bPharmaRadar360en2026-09-16T14:12:29.000ZLegend Biotech names Novartis veteran Ingrid Zhang as new CEOhttps://www.pharmaradar360.com/article/acrp-unveils-theme-for-2027-annual-conference-d04f966c0b3615d9PharmaRadar360en2026-09-16T14:09:13.000ZACRP Unveils Theme for 2027 Annual Conferencehttps://www.pharmaradar360.com/article/scientists-find-an-immune-false-alarm-that-may-drive-rapid-aging-00104e3c1b86bb4ePharmaRadar360en2026-09-16T14:05:35.000ZScientists find an immune “false alarm” that may drive rapid aginghttps://www.pharmaradar360.com/article/celebrating-what-holds-us-on-iphone-18-pro-f697be91e8bd515cPharmaRadar360en2026-09-16T13:59:28.000ZCelebrating “What Holds Us” on iPhone 18 Prohttps://www.pharmaradar360.com/article/carolina-housing-is-built-on-student-feedback-2c16247fc949a7a2PharmaRadar360en2026-09-16T13:58:05.000ZCarolina Housing is built on student feedbackhttps://www.pharmaradar360.com/article/eschback-launches-leader-standard-work-capability-in-seqonis-platform-d6bbb1809a7eb5ffPharmaRadar360en2026-09-16T13:54:48.000Zeschback launches Leader Standard Work capability in Seqonis platformhttps://www.pharmaradar360.com/article/collegium-pharmaceutical-at-h-c-wainwright-pushing-beyond-pain-by-investing-com-7acb87745e02bc6aPharmaRadar360en2026-09-16T13:45:04.000ZCollegium Pharmaceutical at H.C. Wainwright: pushing beyond pain By Investing.comhttps://www.pharmaradar360.com/article/arrowhead-achieves-clinical-validation-for-new-drug-platform-a8d024929ce7f48ePharmaRadar360en2026-09-16T13:39:14.000ZArrowhead Achieves Clinical Validation for New Drug Platformhttps://www.pharmaradar360.com/article/sen-warren-demands-to-see-trump-drug-pricing-pharma-contracts-accuses-rfk-jr-of-b2c1b39832ead5dbPharmaRadar360en2026-09-16T13:36:24.000ZSen. Warren demands to see Trump drug-pricing pharma contracts, accuses RFK Jr. of hiding themhttps://www.pharmaradar360.com/article/could-tracking-genetics-help-stop-myeloma-before-it-starts-371308d2ffb3b266PharmaRadar360en2026-09-16T13:31:31.000ZCould tracking genetics help stop myeloma before it starts?https://www.pharmaradar360.com/article/10-ai-biotech-firms-in-northern-metropolis-to-get-early-cross-border-data-access-8d6ce46540846e4ePharmaRadar360en2026-09-16T13:31:25.000Z10 AI, biotech firms in Northern Metropolis to get early cross-border data accesshttps://www.pharmaradar360.com/article/heart-risks-provider-misconduct-and-a-21-year-old-s-6b7a9c26ed278664PharmaRadar360en2026-09-16T13:30:10.000ZHeart Risks, Provider Misconduct, and a 21-Year-Old's…https://www.pharmaradar360.com/article/covid-19-vaccination-information-for-healthcare-practitioners-2a8cecfc3a4c1e42PharmaRadar360en2026-09-16T13:30:00.000ZCOVID-19 vaccination: information for healthcare practitionershttps://www.pharmaradar360.com/article/pre-submission-advice-support-for-innovative-medicines-b8e46373a16aa9afPharmaRadar360en2026-09-16T13:16:15.000ZPre-submission Advice & Support for Innovative Medicineshttps://www.pharmaradar360.com/article/national-assessment-procedure-for-medicines-5034d11e20bd2b10PharmaRadar360en2026-09-16T13:15:35.000ZNational assessment procedure for medicineshttps://www.pharmaradar360.com/article/biotech-pre-market-movers-meds-tpst-cupr-chart-the-course-b8cbe9650f92187bPharmaRadar360en2026-09-16T13:15:00.000ZBiotech Pre-Market Movers: MEDS, TPST, CUPR Chart The Coursehttps://www.pharmaradar360.com/article/medicines-apply-for-a-variation-to-your-marketing-authorisation-bc0e2a85d91fcf38PharmaRadar360en2026-09-16T13:14:52.000ZMedicines: apply for a variation to your marketing authorisationhttps://www.pharmaradar360.com/article/the-pbm-entity-no-pharmaceutical-company-directly-contracted-with-15e0f87edc35ede0PharmaRadar360en2026-09-16T13:14:34.000ZThe PBM Entity No Pharmaceutical Company Directly Contracted Withhttps://www.pharmaradar360.com/article/un-projet-de-recherche-pour-en-finir-avec-le-risque-de-noyade-des-personnes-lary-6ad6ce0ec9a9cf84PharmaRadar360en2026-09-16T13:13:47.000ZUn projet de recherche pour en finir avec le risque de noyade des personnes laryngectomiséeshttps://www.pharmaradar360.com/article/the-nih-funding-crisis-that-could-reshape-biotech-for-years-to-come-b62b5f7bdd7a60dePharmaRadar360en2026-09-16T13:10:45.000ZThe NIH funding crisis that could reshape biotech for years to comehttps://www.pharmaradar360.com/article/legend-biotech-names-ex-novartis-exec-as-ceo-601341f40ad47d08PharmaRadar360en2026-09-16T13:10:17.000ZLegend Biotech names ex-Novartis exec as CEOhttps://www.pharmaradar360.com/article/calgary-based-biotech-founders-announced-as-recipients-of-canada-s-top-40-under-01c6c7755adde338PharmaRadar360en2026-09-16T13:10:00.000ZCalgary-Based Biotech Founders Announced as Recipients of Canada's Top 40 Under 40® Award for 2026https://www.pharmaradar360.com/article/naoko-takebe-md-phd-joins-wilmot-to-build-early-phase-clinical-trials-and-develo-7441cb8dd9acd00ePharmaRadar360en2026-09-16T13:08:28.000ZNaoko Takebe, MD, PhD, Joins Wilmot to Build Early-Phase Clinical Trials and Developmental Therapeuticshttps://www.pharmaradar360.com/article/sinphar-pharmaceutical-fy2026-h1-earnings-call-gross-margin-hits-record-45-4-aug-2c92cc8d92f59c34PharmaRadar360en2026-09-16T13:04:00.000Z[Sinphar Pharmaceutical FY2026 H1 Earnings Call] Gross Margin Hits Record 45.4%, August Revenue Surges 21.6% YoY; NT$700 Million Yilan Smart Logistics Center Aims to Capture Japan and ASEAN Ordershttps://www.pharmaradar360.com/article/notifiable-diseases-causative-agents-reports-for-2026-32900b46450305d4PharmaRadar360en2026-09-16T13:00:01.000ZNotifiable diseases: causative agents reports for 2026https://www.pharmaradar360.com/article/covid-19-vaccine-5-years-and-over-pgd-and-vgd-6776102a716b3a92PharmaRadar360en2026-09-16T13:00:01.000ZCOVID-19 vaccine (5 years and over) PGD and VGDhttps://www.pharmaradar360.com/article/covid-19-the-green-book-chapter-d276b249e49e4dc1PharmaRadar360en2026-09-16T13:00:01.000ZCOVID-19: the green book chapterhttps://www.pharmaradar360.com/article/finally-a-chance-to-breathe-christiana-gets-care-for-hirschsprung-s-disease-c3e13beb67f44b5aPharmaRadar360en2026-09-16T13:00:00.000ZFinally a chance to breathe: Christiana gets care for Hirschsprung’s diseasehttps://www.pharmaradar360.com/article/pharmaceutical-manufacturing-plant-setup-in-india-9388a1cfa87e6157PharmaRadar360en2026-09-16T12:54:07.000ZPharmaceutical Manufacturing Plant Setup in Indiahttps://www.pharmaradar360.com/article/scientists-find-the-whole-grain-sweet-spot-for-better-heart-health-74fe8c2892b5b3afPharmaRadar360en2026-09-16T12:52:48.000ZScientists find the whole grain “sweet spot” for better heart healthhttps://www.pharmaradar360.com/article/ufrj-concede-titulo-de-professora-emerita-a-ana-luiza-coelho-netto-07641e2218bdf689PharmaRadar360en2026-09-16T12:52:12.000ZUFRJ concede título de Professora Emérita à Ana Luiza Coelho Nettohttps://www.pharmaradar360.com/article/oncology-biotech-news-key-moves-to-watch-in-september-2026-78cb8609a164864fPharmaRadar360en2026-09-16T12:42:22.000ZOncology biotech news: key moves to watch in September 2026https://www.pharmaradar360.com/article/west-pharmaceutical-cuts-98-scottsdale-jobs-after-product-sale-02c12ed5bda7592ePharmaRadar360en2026-09-16T12:39:00.000ZWest Pharmaceutical cuts 98 Scottsdale jobs after product salehttps://www.pharmaradar360.com/article/novartis-pays-sironax-125m-to-acquire-platform-for-crossing-the-blood-brain-barr-57efc9bfdd6fbe18PharmaRadar360en2026-09-16T12:32:15.000ZNovartis pays Sironax $125M to acquire platform for crossing the blood-brain barrierhttps://www.pharmaradar360.com/article/ciclo-de-talleres-para-investigadores-de-la-unlp-2026-tercera-edicion-d1bb67ca66d66070PharmaRadar360en2026-09-16T12:31:46.000ZCiclo de talleres para investigadores de la UNLP 2026 | Tercera ediciónhttps://www.pharmaradar360.com/article/looking-beyond-short-term-turmoil-syngene-is-investing-for-the-future-ff2542fffd1088f1PharmaRadar360en2026-09-16T12:29:45.000ZLooking beyond short-term turmoil, Syngene is investing for the futurehttps://www.pharmaradar360.com/article/vivosim-labs-unveils-new-namkindtm-drug-toxicity-data-at-eurotox-2026-demonstrat-7c307c64eb413c4ePharmaRadar360en2026-09-16T12:26:15.000ZVivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCshttps://www.pharmaradar360.com/article/curiosity-guides-law-school-s-first-strait-fellow-1018a0e7604d6563PharmaRadar360en2026-09-16T12:26:02.000ZCuriosity guides law school’s first Strait Fellowhttps://www.pharmaradar360.com/article/optimi-health-opth-lines-up-phase-3-mdma-ptsd-trial-for-veterans-5e5dca7bb97f51cbPharmaRadar360en2026-09-16T12:25:31.000ZOptimi Health (OPTH) lines up Phase 3 MDMA PTSD trial for veteranshttps://www.pharmaradar360.com/article/optimi-health-expands-clinical-program-with-phase-3-trial-evaluating-mdma-assist-3138d9050b7df197PharmaRadar360en2026-09-16T12:25:00.000ZOptimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorderhttps://www.pharmaradar360.com/article/xenetic-to-merge-with-santersus-ceding-85-of-combined-biotech-to-swiss-investors-38ce4de6437ed570PharmaRadar360en2026-09-16T12:21:45.000ZXenetic to merge with Santersus, ceding 85% of combined biotech to Swiss investorshttps://www.pharmaradar360.com/article/guidance-covid-19-test-validation-approved-products-67c87baa13be15b5PharmaRadar360en2026-09-16T12:17:31.000ZGuidance: COVID-19 test validation approved productshttps://www.pharmaradar360.com/article/without-bacteria-or-chemicals-how-methanol-and-formaldehyde-form-abiotically-in-8f865ceb512ae516PharmaRadar360en2026-09-16T12:07:45.000ZWithout Bacteria or Chemicals: How Methanol and Formaldehyde Form Abiotically in Naturehttps://www.pharmaradar360.com/article/rezera-announces-plans-to-launch-the-reveal-pad-multi-center-study-investigating-8bbac5a19abb9435PharmaRadar360en2026-09-16T12:04:50.000ZRezera Announces Plans to Launch the REVEAL-PAD Multi-Center Study Investigating the Role of Inflammation in Patients with Peripheral Artery Diseasehttps://www.pharmaradar360.com/article/kendall-square-biotech-incubator-launches-program-to-draw-international-startups-e128c3dc2e07ddaaPharmaRadar360en2026-09-16T12:00:47.000ZKendall Square Biotech Incubator Launches Program to Draw International Startupshttps://www.pharmaradar360.com/article/rolling-with-the-waves-ac90c33b7cf09730PharmaRadar360en2026-09-16T12:00:00.000ZRolling with the waveshttps://www.pharmaradar360.com/article/women-s-experiences-accessing-health-information-online-trusted-sources-and-cont-1be2bf56f59deca5PharmaRadar360en2026-09-16T12:00:00.000ZWomen’s Experiences Accessing Health Information Online: Trusted Sources and Contraceptive Informationhttps://www.pharmaradar360.com/article/platinum-naturals-easymulti-stress-men-affected-lots-incorrectly-labelled-for-vi-317c64c8990d36f5PharmaRadar360en2026-09-16T12:00:00.000ZPlatinum Naturals Easymulti Stress (men): Affected lots incorrectly labelled for Vitamin B6 quantityhttps://www.pharmaradar360.com/article/the-banana-faces-an-existential-threat-can-biotech-save-it-6fa7858cd1651577PharmaRadar360en2026-09-16T12:00:00.000ZThe Banana Faces An Existential Threat. Can Biotech Save It?https://www.pharmaradar360.com/article/pharmaceutical-industry-accelerates-supply-chain-heat-decarbonization-e278b969d389bdedPharmaRadar360en2026-09-16T11:51:10.000ZPharmaceutical industry accelerates supply chain heat decarbonizationhttps://www.pharmaradar360.com/article/professor-dr-jakob-nikolas-kather-wird-hopp-stiftungsprofessor-fur-kunstliche-in-8b53026d890c4691PharmaRadar360en2026-09-16T11:50:59.000ZProfessor Dr. Jakob Nikolas Kather wird Hopp-Stiftungsprofessor für „Künstliche Intelligenz in der Medizin“ und Gründungsdirektor des neuen Institute for Medical AI (IMAI) in Heidelberghttps://www.pharmaradar360.com/article/is-west-pharmaceutical-services-stock-outperforming-the-nasdaq-0f730f5a4482fb08PharmaRadar360en2026-09-16T11:50:08.000ZIs West Pharmaceutical Services Stock Outperforming the Nasdaq?https://www.pharmaradar360.com/article/globalpharma-and-princefarma-sign-mou-to-advance-pharmaceutical-distribution-in-e4c13edf0ce21061PharmaRadar360en2026-09-16T11:48:55.000ZGlobalpharma And PrinceFarma Sign MoU To Advance Pharmaceutical Distribution In Angolahttps://www.pharmaradar360.com/article/in-memoriam-rob-van-der-wal-8b01f45490929bc1PharmaRadar360en2026-09-16T11:34:00.000ZIn memoriam Rob van der Walhttps://www.pharmaradar360.com/article/abeona-therapeutics-announces-activation-of-university-of-florida-health-as-newe-84699260c629525cPharmaRadar360en2026-09-16T11:30:00.000ZAbeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®https://www.pharmaradar360.com/article/ascendis-regains-obesity-rights-as-novo-exits-monthly-glp-1-deal-cf9dc0b84009e824PharmaRadar360en2026-09-16T11:27:54.000ZAscendis regains obesity rights as Novo exits monthly GLP-1 dealhttps://www.pharmaradar360.com/article/opportunities-for-patients-and-the-public-to-be-involved-in-the-work-of-the-mhra-f3c0f65f319949e0PharmaRadar360en2026-09-16T11:27:49.000ZOpportunities for patients and the public to be involved in the work of the MHRAhttps://www.pharmaradar360.com/article/europe-s-5bn-scaleup-fund-will-not-fix-biotech-s-funding-gap-even-its-backers-sa-4944433c0dc34ac8PharmaRadar360en2026-09-16T11:17:46.000ZEurope’s €5bn scaleup fund will not fix biotech’s funding gap. Even its backers say sohttps://www.pharmaradar360.com/article/expres2ion-biotech-sek19-3m-to-13-guarantee-and-a-sek50m-equity-facility-5269a621b698e7d9PharmaRadar360en2026-09-16T11:06:00.000ZExpreS2ion Biotech: SEK19.3m TO 13 guarantee and a SEK50m equity facilityhttps://www.pharmaradar360.com/article/sling-therapeutics-announces-first-patients-dosed-in-global-phase-3-orbit-pivota-d75552e00382cd47PharmaRadar360en2026-09-16T11:05:00.000ZSling Therapeutics Announces First Patients Dosed in Global Phase 3 ORBIT Pivotal Trial of Linsitinib for Thyroid Eye Diseasehttps://www.pharmaradar360.com/article/guidance-national-patient-safety-alert-supporting-information-patient-hoists-and-481832dd1483a5a5PharmaRadar360en2026-09-16T11:04:57.000ZGuidance: National Patient Safety Alert Supporting Information. Patient hoists and slings: incidents and case examples.https://www.pharmaradar360.com/article/national-patient-safety-alert-patient-hoists-and-slings-all-types-risk-of-death-96b745c6c3886211PharmaRadar360en2026-09-16T11:01:57.000ZNational Patient Safety Alert: Patient hoists and slings (all types): risk of death and serious harm from falls (NatPSA/2026/005/MHRA)https://www.pharmaradar360.com/article/human-neurons-flourish-in-mouse-brains-offering-a-new-view-of-neurodevelopmental-ee7d34769d2e1775PharmaRadar360en2026-09-16T11:00:00.000ZHuman neurons flourish in mouse brains, offering a new view of neurodevelopmental disordershttps://www.pharmaradar360.com/article/sling-therapeutics-announces-123-million-series-c-financing-to-advance-phase-3-d-5cf553c7190d4864PharmaRadar360en2026-09-16T11:00:00.000ZSling Therapeutics Announces $123 Million Series C Financing to Advance Phase 3 Development of its Oral Small Molecule IGF-1R Inhibitor for Thyroid Eye Diseasehttps://www.pharmaradar360.com/article/sling-gets-123m-for-phase-3-trial-of-ex-astellas-drug-in-thyroid-eye-disease-3e28cc7677d34261PharmaRadar360en2026-09-16T11:00:00.000ZSling gets $123M for Phase 3 trial of ex-Astellas drug in thyroid eye diseasehttps://www.pharmaradar360.com/article/idexx-laboratories-acquires-covetai-to-advance-veterinary-workflow-intelligence-81cfc6189054a50dPharmaRadar360en2026-09-16T11:00:00.000ZIDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligencehttps://www.pharmaradar360.com/article/la-aemps-informa-de-la-actualizacion-de-la-informacion-de-seguridad-de-los-medic-9860b82efb555986PharmaRadar360en2026-09-16T10:59:13.000ZLa AEMPS informa de la actualización de la información de seguridad de los medicamentos veterinarios que contienen fenobarbitalhttps://www.pharmaradar360.com/article/bristol-myers-squibb-announces-dividend-1d1e3cf8ca63c361PharmaRadar360en2026-09-16T10:59:00.000ZBristol Myers Squibb Announces Dividendhttps://www.pharmaradar360.com/article/la-aemps-recuerda-como-evitar-errores-de-medicacion-por-sobredosificacion-con-vi-e10c84f344062da2PharmaRadar360en2026-09-16T10:47:51.000ZLa AEMPS recuerda cómo evitar errores de medicación por sobredosificación con vitamina Dhttps://www.pharmaradar360.com/article/msd-7b118228b3a79e32PharmaRadar360en2026-09-16T10:43:00.000Zペムブロリズマブ適正使用のお願い_白金系抗悪性腫瘍剤抵抗性の再発卵巣癌（MSD株式会社）https://www.pharmaradar360.com/article/sclerodermia-humanitas-partecipa-alla-giornata-del-ciclamino-ef1b80297605f7c9PharmaRadar360en2026-09-16T10:42:44.000ZSclerodermia: Humanitas partecipa alla Giornata del ciclaminohttps://www.pharmaradar360.com/article/six-neighbourhood-health-trailblazers-to-transform-care-e6da2526d470fa64PharmaRadar360en2026-09-16T10:41:35.000ZSix neighbourhood health trailblazers to transform carehttps://www.pharmaradar360.com/article/tiedonhankinnan-tuokiot-syksylla-2026-2a2791a37b53bdb0PharmaRadar360en2026-09-16T10:31:27.000ZTiedonhankinnan tuokiot syksyllä 2026https://www.pharmaradar360.com/article/medtronic-announces-fda-clearance-for-ligasuretm-ras-maryland-instrument-on-the-adeda03ace33da07PharmaRadar360en2026-09-16T10:30:00.000ZMedtronic announces FDA clearance for LigaSure™ RAS Maryland instrument on the Hugo™ RAS systemhttps://www.pharmaradar360.com/article/should-you-invest-in-the-vaneck-biotech-etf-bbh-03686cfedea3aa38PharmaRadar360en2026-09-16T10:20:02.000ZShould You Invest in the VanEck Biotech ETF (BBH)?https://www.pharmaradar360.com/article/ingrid-zhang-appointed-ceo-of-legend-biotech-amid-mid-september-2026-industry-le-5ed0fa87667a5ca9PharmaRadar360en2026-09-16T10:15:30.000ZIngrid Zhang Appointed CEO of Legend Biotech Amid Mid-September 2026 Industry Leadership Changeshttps://www.pharmaradar360.com/article/tv-drug-ads-could-lose-their-website-shortcut-for-risk-details-under-an-fda-rule-bc0a0495d16ec398PharmaRadar360en2026-09-16T10:15:06.000ZTV Drug Ads Could Lose Their Website Shortcut for Risk Details Under an FDA Rule Planned for Decemberhttps://www.pharmaradar360.com/article/9ad3c82bb027f830PharmaRadar360en2026-09-16T10:08:15.000Zペムブロリズマブ（遺伝子組換え）製剤の最適使用推進ガイドライン（卵巣癌）について（厚生労働省）https://www.pharmaradar360.com/article/beyond-admet-ai-for-medicines-safety-stakeholder-survey-62ff7205a99e26f8PharmaRadar360en2026-09-16T10:08:02.000ZBeyond ADMET: AI for medicines safety stakeholder surveyhttps://www.pharmaradar360.com/article/charite-warnt-vor-personalabbau-und-schlechterer-patientenversorgung-954f5acc34729d49PharmaRadar360en2026-09-16T10:07:38.000ZCharité warnt vor Personalabbau und schlechterer Patientenversorgunghttps://www.pharmaradar360.com/article/8f0cd19707f1caf3PharmaRadar360en2026-09-16T10:06:46.000Zチスレリズマブ（遺伝子組換え）製剤の最適使用推進ガイドライン（上咽頭癌）の作成及び最適使用推進ガイドライン（食道癌及び胃癌）の一部改正について（厚生労働省）https://www.pharmaradar360.com/article/775198a373c05713PharmaRadar360en2026-09-16T10:05:06.000Zトボラフェニブ製剤の使用に当たっての留意事項について（厚生労働省）https://www.pharmaradar360.com/article/4644adfcfbaf2ab9PharmaRadar360en2026-09-16T10:03:40.000Zミルベツキシマブ ソラブタンシン（遺伝子組換え）製剤の使用に当たっての留意事項について（厚生労働省）https://www.pharmaradar360.com/article/ctt-pharma-corporate-updates-7cb9f05535b4eb81PharmaRadar360en2026-09-16T10:00:03.000ZCTT Pharma Corporate Updateshttps://www.pharmaradar360.com/article/digitaler-zwilling-soll-brustkrebspravention-individueller-machen-65208fd48426370bPharmaRadar360en2026-09-16T09:54:27.000ZDigitaler Zwilling soll Brustkrebsprävention individueller machenhttps://www.pharmaradar360.com/article/ers-2026-obesity-an-independent-obstruction-to-biologic-treated-asthma-8fe9aca8139f27b2PharmaRadar360en2026-09-16T09:44:39.000ZERS 2026: obesity, an independent obstruction to biologic-treated asthmahttps://www.pharmaradar360.com/article/home-treatments-drive-smarter-sustainable-pharmaceutical-packaging-38172df7a6199e47PharmaRadar360en2026-09-16T09:36:51.000ZHome treatments drive smarter, sustainable pharmaceutical packaginghttps://www.pharmaradar360.com/article/clinical-trials-for-medicines-good-clinical-practice-inspections-a1362df4adb5e02bPharmaRadar360en2026-09-16T09:36:23.000ZClinical trials for medicines: Good clinical practice inspectionshttps://www.pharmaradar360.com/article/reunion-del-comite-de-medicamentos-de-uso-humano-de-septiembre-de-2026-cf9a2cb6077912c0PharmaRadar360en2026-09-16T09:32:00.000ZReunión del Comité de Medicamentos de Uso Humano de septiembre de 2026https://www.pharmaradar360.com/article/trump-administration-shift-puts-this-corner-of-biotech-back-in-favor-9c761ffe135492bbPharmaRadar360en2026-09-16T09:30:00.000ZTrump Administration Shift Puts This Corner of Biotech Back in Favorhttps://www.pharmaradar360.com/article/kim-yong-min-named-2026-jw-sungcheon-award-recipient-85a5f990849a0bc3PharmaRadar360en2026-09-16T09:27:13.000ZKim Yong-min Named 2026 JW Sungcheon Award Recipienthttps://www.pharmaradar360.com/article/daewoong-pharmaceutical-wins-2026-national-contribution-award-05149f7f49635776PharmaRadar360en2026-09-16T09:27:00.000ZDaewoong Pharmaceutical Wins 2026 National Contribution Awardhttps://www.pharmaradar360.com/article/kpbma-holds-korea-thailand-pharmaceutical-forum-in-bangkok-ec594cbe6f8df10bPharmaRadar360en2026-09-16T09:26:59.000ZKPBMA Holds Korea-Thailand Pharmaceutical Forum in Bangkokhttps://www.pharmaradar360.com/article/quotient-sciences-named-among-gen-s-10-cdmo-up-comers-2026-b8121582b4e6e4a1PharmaRadar360en2026-09-16T09:26:34.000ZQuotient Sciences Named Among GEN’s 10 CDMO Up & Comers 2026https://www.pharmaradar360.com/article/fda-holds-public-hearing-on-psychedelic-drugs-as-trump-driven-push-gathers-pace-c37ed3be97b94076PharmaRadar360en2026-09-16T09:25:38.000ZFDA holds public hearing on psychedelic drugs as Trump-driven push gathers pacehttps://www.pharmaradar360.com/article/how-ai-is-reshaping-the-cdmo-sponsor-relationship-dbb6c49855c23d14PharmaRadar360en2026-09-16T09:10:04.000ZHow AI Is Reshaping the CDMO-Sponsor Relationshiphttps://www.pharmaradar360.com/article/are-we-underestimating-the-pharmaceutical-potential-of-the-cannabis-plant-579d1a341447e83fPharmaRadar360en2026-09-16T08:47:26.000ZAre We Underestimating the Pharmaceutical Potential of the Cannabis Plant?https://www.pharmaradar360.com/article/domestic-pharmaceutical-and-bio-stocks-which-are-considered-representative-growt-3fc642a021ab05a4PharmaRadar360en2026-09-16T08:47:06.000ZDomestic pharmaceutical and bio stocks, which are considered representative growth industries alonghttps://www.pharmaradar360.com/article/korea-establishes-public-private-pharmaceutical-industry-innovation-council-647569a7800a757dPharmaRadar360en2026-09-16T08:44:34.000ZKorea establishes public-private pharmaceutical industry innovation councilhttps://www.pharmaradar360.com/article/helsinki-animal-law-seminar-xin-zheng-28-10-2026-b66334489694a403PharmaRadar360en2026-09-16T08:36:10.000ZHelsinki Animal Law Seminar: Xin Zheng 28.10.2026https://www.pharmaradar360.com/article/meddra-29-1-e37560fd41624dadPharmaRadar360en2026-09-16T08:33:10.000ZMedDRA 29.1https://www.pharmaradar360.com/article/sex-ratios-at-birth-in-the-uk-2019-to-2023-e85b4ee4f5630c49PharmaRadar360en2026-09-16T08:30:04.000ZSex ratios at birth in the UK: 2019 to 2023https://www.pharmaradar360.com/article/migrant-health-country-of-origin-health-protection-advice-712e66654b02af33PharmaRadar360en2026-09-16T08:30:03.000ZMigrant health: country-of-origin health protection advicehttps://www.pharmaradar360.com/article/sex-ratios-at-birth-in-the-uk-2018-to-2022-2e081caa376a5196PharmaRadar360en2026-09-16T08:30:03.000ZSex ratios at birth in the UK: 2018 to 2022https://www.pharmaradar360.com/article/sti-quarterly-surveillance-reports-provisional-data-24f79f77d1898abfPharmaRadar360en2026-09-16T08:30:03.000ZSTI quarterly surveillance reports: provisional datahttps://www.pharmaradar360.com/article/uk-clinical-research-delivery-key-performance-indicators-95d573354d6fb70dPharmaRadar360en2026-09-16T08:30:03.000ZUK Clinical Research Delivery key performance indicatorshttps://www.pharmaradar360.com/article/uk-clinical-research-delivery-key-performance-indicators-data-to-august-2026-a91ff0b95960e676PharmaRadar360en2026-09-16T08:30:02.000ZUK Clinical Research Delivery key performance indicators: data to August 2026https://www.pharmaradar360.com/article/bovine-tuberculosis-tb-public-health-management-466209379572520bPharmaRadar360en2026-09-16T08:30:02.000ZBovine tuberculosis (TB): public health managementhttps://www.pharmaradar360.com/article/survey-into-the-radiological-impact-of-the-routine-transport-of-radiopharmaceuti-80b294175a4a0760PharmaRadar360en2026-09-16T08:30:01.000ZSurvey into the Radiological Impact of the Routine Transport of Radiopharmaceuticals in the UKhttps://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32PharmaRadar360en2026-09-16T08:24:50.000ZExcipient Selection Strategies to Mitigate Nitrosamine Riskshttps://www.pharmaradar360.com/article/helsinki-animal-law-seminar-david-john-holroyd-17-9-2026-ea05ec76417c45c4PharmaRadar360en2026-09-16T08:22:31.000ZHelsinki Animal Law Seminar: David John Holroyd 17.9.2026https://www.pharmaradar360.com/article/toward-canonical-helm-representations-for-sequence-level-peptide-registration-d7409182dc2c1913PharmaRadar360en2026-09-16T08:18:27.000ZToward Canonical HELM Representations for Sequence-Level Peptide Registrationhttps://www.pharmaradar360.com/article/9-25-jsmo-kfcr-408a09bcda0795e9PharmaRadar360en2026-09-16T08:09:16.000Z【※申請締め切り：9月25日（金）】JSMO／KFCR＊ 公募型若手研究助成についてhttps://www.pharmaradar360.com/article/a-new-system-enables-the-early-detection-of-drug-induced-liver-toxicities-in-pri-3a721253fe2bd48ePharmaRadar360en2026-09-16T08:00:00.000ZA new system enables the early detection of drug-induced liver toxicities in primary carehttps://www.pharmaradar360.com/article/us-biotech-corefx-chooses-cork-as-its-european-r-d-hq-718cbbd0532ecf2cPharmaRadar360en2026-09-16T07:55:42.000ZUS biotech CoreFX chooses Cork as its European R&D HQhttps://www.pharmaradar360.com/article/wuxi-biologics-named-to-forbes-china-esg-50-list-2026-for-green-crdmo-and-digita-732f52b3717008fcPharmaRadar360en2026-09-16T07:54:09.000ZWuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG Leadershiphttps://www.pharmaradar360.com/article/helsinki-animal-law-seminar-laura-ervo-23-9-2026-27784238907df25bPharmaRadar360en2026-09-16T07:53:26.000ZHelsinki Animal Law Seminar: Laura Ervo 23.9.2026https://www.pharmaradar360.com/article/four-decades-of-discovery-at-embl-2b387676ab26e237PharmaRadar360en2026-09-16T07:48:47.000ZFour decades of discovery at EMBLhttps://www.pharmaradar360.com/article/building-a-clear-picture-of-uk-health-research-funding-5fb0da3202bb024bPharmaRadar360en2026-09-16T07:41:32.000ZBuilding a clear picture of UK health research fundinghttps://www.pharmaradar360.com/article/shinpoong-seeks-phase-3-ind-amendment-for-stroke-drug-sp-8203-7c73c2ad1ef58a01PharmaRadar360en2026-09-16T07:19:15.000ZShinpoong seeks phase 3 IND amendment for stroke drug SP-8203https://www.pharmaradar360.com/article/l-essentiel-de-la-generosite-2025-3705f63f541d6466PharmaRadar360en2026-09-16T07:14:44.000ZL’essentiel de la générosité 2025https://www.pharmaradar360.com/article/ai-is-changing-the-talent-biotech-companies-compete-to-hire-6b1fee41fba14396PharmaRadar360en2026-09-16T07:01:38.000ZAI is changing the talent biotech companies compete to hirehttps://www.pharmaradar360.com/article/unmc-brings-ai-expertise-to-6-million-nsf-crop-resilience-project-806a9377b6c1a0e4PharmaRadar360en2026-09-16T07:00:00.000ZUNMC brings AI expertise to $6 million NSF crop resilience projecthttps://www.pharmaradar360.com/article/more-than-1-500-patients-have-taken-part-in-the-clinic-prehabilitation-program-f8328961b65fbbb2PharmaRadar360en2026-09-16T06:58:00.000ZMore than 1,500 patients have taken part in the Clínic Prehabilitation Programhttps://www.pharmaradar360.com/article/decarolis-named-director-of-sponsored-programs-administration-ff1c9934438d7007PharmaRadar360en2026-09-16T06:56:00.000ZDeCarolis named director of Sponsored Programs Administrationhttps://www.pharmaradar360.com/article/center-for-healthy-living-hosts-open-house-through-sept-24-b8c9d6e946465d6cPharmaRadar360en2026-09-16T06:54:00.000ZCenter for Healthy Living hosts open house through Sept. 24https://www.pharmaradar360.com/article/chri-events-examine-advances-in-pediatric-cancer-brain-tumor-research-6b49e60b0a555f4ePharmaRadar360en2026-09-16T06:52:00.000ZCHRI events examine advances in pediatric cancer, brain tumor researchhttps://www.pharmaradar360.com/article/trutakna-meets-all-endpoints-in-phase-3-iga-nephropathy-trial-final-analysis-b7255873d1b753fbPharmaRadar360en2026-09-16T06:46:54.000ZTRUTAKNA Meets All Endpoints in Phase 3 IgA Nephropathy Trial Final Analysishttps://www.pharmaradar360.com/article/crb-913-obesity-drug-shows-5-weight-loss-in-phase-1b-trial-3275d98d0fe2e371PharmaRadar360en2026-09-16T06:46:54.000ZCRB-913 Obesity Drug Shows 5% Weight Loss in Phase 1b Trialhttps://www.pharmaradar360.com/article/foundationone-cdx-braf-v600-braf-31eefd4b67f97474PharmaRadar360en2026-09-16T06:30:00.000ZFoundationOne CDx がんゲノムプロファイル、BRAF V600変異及びBRAF融合遺伝子陽性の神経膠腫に対するトボラフェニブのコンパニオン診断として承認を取得https://www.pharmaradar360.com/article/chugai-obtains-approval-for-foundationone-cdx-cancer-genomic-profile-as-a-compan-26f849ad79ecca25PharmaRadar360en2026-09-16T06:30:00.000ZChugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Tovorafenib for BRAF V600 Alterations and BRAF Fusion Gene-Positive Gliomahttps://www.pharmaradar360.com/article/zymfentra-xcopri-projected-to-become-korea-s-1st-1-billion-blockbuster-drugs-in-1b9ece210cf9d90aPharmaRadar360en2026-09-16T06:19:22.000ZZymfentra, Xcopri projected to become Korea’s 1st $1 billion blockbuster drugs in 2027https://www.pharmaradar360.com/article/avacta-achieves-clinical-proof-of-mechanism-for-the-next-generation-of-pre-cisio-a3abc4b621039f07PharmaRadar360en2026-09-16T06:02:44.000ZAvacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trialhttps://www.pharmaradar360.com/article/sa-har-vgr-byggt-en-modell-for-specialistlakares-fortbildning-da64b4d7e3b0264fPharmaRadar360en2026-09-16T06:00:52.000ZSå har VGR byggt en modell för specialistläkares fortbildninghttps://www.pharmaradar360.com/article/vom-spitalbett-in-den-olympia-bob-2b5738cc36b7f3c2PharmaRadar360en2026-09-16T06:00:03.000ZVom Spitalbett in den Olympia-Bobhttps://www.pharmaradar360.com/article/legend-biotech-names-new-ceo-96784a8d02bcdd18PharmaRadar360en2026-09-16T05:52:35.000ZLegend Biotech names new CEOhttps://www.pharmaradar360.com/article/biotech-stocks-at-52-week-highs-mnov-8-rvty-8-txg-6-tlx-9-sdgr-12-7011727fdf19ea41PharmaRadar360en2026-09-16T05:21:00.000ZBiotech Stocks At 52-Week Highs - MNOV +8%, RVTY +8%, TXG +6%, TLX +9%, SDGR +12%https://www.pharmaradar360.com/article/maharashtra-fda-suspends-cafe-mondegar-licence-over-food-safety-violations-ffef6c2b8885044bPharmaRadar360en2026-09-16T05:08:22.000ZMaharashtra FDA suspends Cafe Mondegar licence over food safety violationshttps://www.pharmaradar360.com/article/dengiall-india-s-first-indigenous-dengue-vaccine-could-arrive-by-2027-3fcef4b37a7f1fedPharmaRadar360en2026-09-16T04:34:01.000ZDengiAll: India's first indigenous dengue vaccine could arrive by 2027https://www.pharmaradar360.com/article/teva-pharmaceutical-industries-teva-starts-direct-nyse-share-trading-in-shift-fr-49f9efdcc94f4670PharmaRadar360en2026-09-16T04:24:07.000ZTeva Pharmaceutical Industries (TEVA) Starts Direct NYSE Share Trading In Shift From ADShttps://www.pharmaradar360.com/article/takeda-pharmaceutical-tak-insider-sale-chief-transformation-o-d2af8d6500810d52PharmaRadar360en2026-09-16T04:19:48.000ZTakeda Pharmaceutical (TAK) Insider Sale: Chief Transformation Ohttps://www.pharmaradar360.com/article/left-ventricular-pacing-associated-cardiomyopathy-revealing-myocardial-vulnerabi-3cc98d06ff440cacPharmaRadar360en2026-09-16T03:58:14.000ZLeft Ventricular Pacing‐Associated Cardiomyopathy Revealing Myocardial Vulnerability in Congenital Complete Heart Blockhttps://www.pharmaradar360.com/article/global-covid-19-tracker-b43544edf907cec3PharmaRadar360en2026-09-16T03:58:02.000ZGlobal COVID-19 Trackerhttps://www.pharmaradar360.com/article/leadless-pacemaker-implant-location-as-a-predictor-of-pacing-induced-cardiomyopa-3f898d5fd08f03a7PharmaRadar360en2026-09-16T03:52:48.000ZLeadless Pacemaker Implant Location as a Predictor of Pacing Induced Cardiomyopathyhttps://www.pharmaradar360.com/article/alternating-va-intervals-what-is-the-mechanism-eca4f20c1cb4ac08PharmaRadar360en2026-09-16T03:46:22.000ZAlternating VA Intervals, What is the Mechanism?https://www.pharmaradar360.com/article/fuhrendes-biotech-unternehmen-entscheidet-sich-weltweit-fur-veeva-vault-crm-8c0c10dd0f0dba7ePharmaRadar360en2026-09-16T03:45:00.000ZFührendes Biotech-Unternehmen entscheidet sich weltweit für Veeva Vault CRMhttps://www.pharmaradar360.com/article/etfs-investing-in-hangzhou-biotest-biotech-co-ltd-class-a-stocks-fc0b09bee485f86cPharmaRadar360en2026-09-16T03:38:07.000ZETFs Investing in Hangzhou Biotest Biotech Co., Ltd. Class A Stockshttps://www.pharmaradar360.com/article/fda-suspends-licences-of-mumbai-s-iconic-cafe-mondegar-3-other-eateries-6541d36f26d84549PharmaRadar360en2026-09-16T03:23:11.000ZFDA suspends licences of Mumbai's iconic Cafe Mondegar, 3 other eaterieshttps://www.pharmaradar360.com/article/3-clinical-stage-cancer-stocks-with-pristine-balance-sheets-f682c41718245b06PharmaRadar360en2026-09-16T03:09:59.000Z3 Clinical-Stage Cancer Stocks With Pristine Balance Sheetshttps://www.pharmaradar360.com/article/pharmosa-biopharm-s-inhaled-drug-l606-wins-china-approval-to-launch-global-phase-ac7ff245c1936bfePharmaRadar360en2026-09-16T03:05:00.000ZPharmosa Biopharm's Inhaled Drug L606 Wins China Approval to Launch Global Phase 3 Trial for Pulmonary Hypertensionhttps://www.pharmaradar360.com/article/tenax-therapeutics-ceo-christopher-giordano-acquires-20-087-in-shares-921f29d813284c41PharmaRadar360en2026-09-16T03:01:00.000ZTenax Therapeutics CEO Christopher Giordano acquires $20,087 in shareshttps://www.pharmaradar360.com/article/ultra-processed-foods-linked-to-hidden-muscle-fat-that-may-threaten-your-knees-d87f3d7b4cce43bdPharmaRadar360en2026-09-16T03:00:57.000ZUltra-processed foods linked to hidden muscle fat that may threaten your kneeshttps://www.pharmaradar360.com/article/us-approves-world-s-first-drug-to-treat-muscle-atrophy-in-sma-5dd33ab3b8a374afPharmaRadar360en2026-09-16T02:58:18.000ZUS approves world’s first drug to treat muscle atrophy in SMAhttps://www.pharmaradar360.com/article/cambium-bio-raises-5m-to-fund-pivotal-phase-3-eye-disease-trial-025f102bc09a7c21PharmaRadar360en2026-09-16T02:52:04.000ZCambium Bio raises $5M to fund pivotal Phase 3 eye disease trialhttps://www.pharmaradar360.com/article/etfs-investing-in-guanhao-biotech-co-ltd-class-a-stocks-b31fd0b4dd031d92PharmaRadar360en2026-09-16T02:46:28.000ZETFs Investing in Guanhao Biotech Co., Ltd. Class A Stockshttps://www.pharmaradar360.com/article/scientists-find-a-hidden-retinal-defense-against-vision-loss-0ba2a68267fea301PharmaRadar360en2026-09-16T02:37:01.000ZScientists find a hidden retinal defense against vision losshttps://www.pharmaradar360.com/article/a-50-anos-los-lapices-siguen-escribiendo-y-son-honoris-causa-de-la-unlp-6c7f199371003580PharmaRadar360en2026-09-16T02:14:57.000ZA 50 años, los Lápices siguen escribiendo y son Honoris Causa de la UNLPhttps://www.pharmaradar360.com/article/a-50-anos-de-su-asesinato-rendimos-homenaje-a-sergio-karakachoff-45d9599f7f2a1eccPharmaRadar360en2026-09-16T02:14:50.000ZA 50 años de su asesinato, rendimos homenaje a Sergio Karakachoffhttps://www.pharmaradar360.com/article/distinguiremos-con-el-doctorado-honoris-causa-a-los-militantes-estudiantiles-de-629241cb090f6c8ePharmaRadar360en2026-09-16T02:14:28.000ZDistinguiremos con el Doctorado Honoris Causa a los militantes estudiantiles de La Noche de los Lápiceshttps://www.pharmaradar360.com/article/gsk-s-us-750-million-cancer-drug-deal-highlights-china-s-rise-as-biotech-player-019202f18c332040PharmaRadar360en2026-09-16T02:00:05.000ZGSK’s US$750 million cancer drug deal highlights China’s rise as biotech playerhttps://www.pharmaradar360.com/article/pharmac-seeks-feedback-on-widening-access-to-febuxostat-for-people-with-gout-3692c364cf534524PharmaRadar360en2026-09-16T02:00:00.000ZPharmac seeks feedback on widening access to febuxostat for people with gouthttps://www.pharmaradar360.com/article/legend-biotech-taps-novartis-veteran-zhang-as-ceo-58cffabf971dd26aPharmaRadar360en2026-09-16T01:55:47.000ZLegend Biotech taps Novartis veteran Zhang as CEOhttps://www.pharmaradar360.com/article/biotech-midweek-pulse-xbi-loses-steam-after-hot-2026-run-here-are-the-stocks-and-7ea3ba7251b2718aPharmaRadar360en2026-09-16T01:51:08.000ZBiotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Nexthttps://www.pharmaradar360.com/article/biotech-midweek-pulse-xbi-loses-steam-after-hot-2026-run-here-are-the-stocks-and-941d72ff3dff7f07PharmaRadar360en2026-09-16T01:51:00.000ZBiotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Nexthttps://www.pharmaradar360.com/article/active-numeracy-welcomes-colleagues-from-tallinn-university-66ce719462cfbd5fPharmaRadar360en2026-09-16T01:41:33.000ZActive Numeracy Welcomes Colleagues from Tallinn Universityhttps://www.pharmaradar360.com/article/scientists-reversed-biological-age-in-older-adults-in-just-4-weeks-738a0a4357926dd9PharmaRadar360en2026-09-16T01:35:54.000ZScientists reversed biological age in older adults in just 4 weekshttps://www.pharmaradar360.com/article/perriello-discusses-biotech-s-future-with-local-leaders-f075c4ce96759b01PharmaRadar360en2026-09-16T01:30:00.000ZPerriello discusses biotech's future with local leadershttps://www.pharmaradar360.com/article/vera-says-phase-3-trutakna-trial-slowed-iga-nephropathy-progression-5e494faeaa8a90adPharmaRadar360en2026-09-16T01:11:26.000ZVera Says Phase 3 Trutakna Trial Slowed IgA Nephropathy Progressionhttps://www.pharmaradar360.com/article/pharmaceutical-executive-survey-finds-emerging-biotech-ceos-increasingly-rely-on-f8dc02c36dd7a25ePharmaRadar360en2026-09-16T00:16:26.000ZPharmaceutical Executive Survey Finds Emerging Biotech CEOs Increasingly Rely on External Advisorshttps://www.pharmaradar360.com/article/legend-biotech-taps-novartis-veteran-zhang-as-ceo-afe8e7e7d5c3f9a6PharmaRadar360en2026-09-16T00:15:45.000ZLegend Biotech taps Novartis veteran Zhang as CEOhttps://www.pharmaradar360.com/article/en-otsuka-pharmaceutical-obtains-marketing-approval-for-enofeed-liquid-for-enter-5c5b3d702f486c51PharmaRadar360en2026-09-16T00:00:00.000ZEN Otsuka Pharmaceutical Obtains Marketing Approval for ENOFEED® Liquid for Enteral Usehttps://www.pharmaradar360.com/article/local-antibody-driven-response-to-anti-pd-1-blockade-c9984854653c1ff1PharmaRadar360en2026-09-16T00:00:00.000ZLocal antibody-driven response to anti-PD-1 blockadehttps://www.pharmaradar360.com/article/establishment-and-characterization-of-primary-retinoblastoma-cell-lines-a-compre-cfac4ec02c19cc2aPharmaRadar360en2026-09-16T00:00:00.000ZEstablishment and characterization of primary retinoblastoma cell lines: a comprehensive molecular profiling approachhttps://www.pharmaradar360.com/article/predictive-and-instructive-cerebellar-encoding-of-dopamine-reward-drives-motivat-a85d22452d6058edPharmaRadar360en2026-09-16T00:00:00.000ZPredictive and instructive cerebellar encoding of dopamine reward drives motivated behaviorhttps://www.pharmaradar360.com/article/hippocampal-astrocytic-sequences-emerge-during-learning-and-memory-recall-8a32f1644356b364PharmaRadar360en2026-09-16T00:00:00.000ZHippocampal astrocytic sequences emerge during learning and memory recallhttps://www.pharmaradar360.com/article/ebv-reactivation-priming-of-the-peripheral-immune-system-in-multiple-sclerosis-r-cd6069644ba7186dPharmaRadar360en2026-09-16T00:00:00.000ZEBV reactivation priming of the peripheral immune system in multiple sclerosis relapsehttps://www.pharmaradar360.com/article/sex-specific-biological-aging-clocks-across-organs-and-omics-83fe2665d8ae7b6dPharmaRadar360en2026-09-16T00:00:00.000ZSex-specific biological aging clocks across organs and omicshttps://www.pharmaradar360.com/article/factor-ix-padua-aav-gene-therapy-in-adolescents-with-hemophilia-b-a-phase-1-tria-51c2bc7b509e2f74PharmaRadar360en2026-09-16T00:00:00.000ZFactor IX Padua AAV gene therapy in adolescents with hemophilia B: a phase 1 trialhttps://www.pharmaradar360.com/article/liquid-biopsy-for-early-detection-of-pancreatic-ductal-adenocarcinoma-6015e08250c6d78ePharmaRadar360en2026-09-16T00:00:00.000ZLiquid biopsy for early detection of pancreatic ductal adenocarcinomahttps://www.pharmaradar360.com/article/fda-approves-pioneering-breast-cancer-drug-that-nips-resistance-in-the-bud-db40981eeca6218dPharmaRadar360en2026-09-16T00:00:00.000ZFDA approves pioneering breast cancer drug that nips resistance in the budhttps://www.pharmaradar360.com/article/mechanisms-of-transcriptional-regulation-by-salicylic-acid-receptors-a6885e265c9723fdPharmaRadar360en2026-09-16T00:00:00.000ZMechanisms of Transcriptional Regulation by Salicylic Acid Receptorshttps://www.pharmaradar360.com/article/inflection-points-and-transitions-in-alzheimer-s-disease-fb32e0e5136c04b1PharmaRadar360en2026-09-16T00:00:00.000ZInflection points and transitions in Alzheimer’s diseasehttps://www.pharmaradar360.com/article/sex-without-crossovers-mimics-clonal-reproduction-in-rhynchospora-tenuis-791dc6305a28390dPharmaRadar360en2026-09-16T00:00:00.000ZSex without crossovers mimics clonal reproduction in Rhynchospora tenuishttps://www.pharmaradar360.com/article/rapid-patient-specific-neural-networks-for-x-ray-to-volume-registration-e12864e6d778fe8fPharmaRadar360en2026-09-16T00:00:00.000ZRapid patient-specific neural networks for X-ray to volume registrationhttps://www.pharmaradar360.com/article/reimagining-research-papers-as-interactive-and-reliable-ai-agents-9751de96eb72d20fPharmaRadar360en2026-09-16T00:00:00.000ZReimagining research papers as interactive and reliable AI agentshttps://www.pharmaradar360.com/article/electroluminescent-photoresists-extending-lithographic-scaling-to-oleds-7b05f7ba1014422aPharmaRadar360en2026-09-16T00:00:00.000ZElectroluminescent photoresists extending lithographic scaling to OLEDshttps://www.pharmaradar360.com/article/evolution-and-heterogeneity-of-lethal-metastatic-bladder-cancer-subtypes-b7ac1772dd8f10dePharmaRadar360en2026-09-16T00:00:00.000ZEvolution and heterogeneity of lethal metastatic bladder cancer subtypeshttps://www.pharmaradar360.com/article/developmental-xenocortication-using-human-derived-organoids-in-mice-cbeb4bb1711cdc6fPharmaRadar360en2026-09-16T00:00:00.000ZDevelopmental xenocortication using human-derived organoids in micehttps://www.pharmaradar360.com/article/mutational-constraints-on-rsv-f-and-its-neutralization-by-antibodies-94134cfac2f3e9e8PharmaRadar360en2026-09-16T00:00:00.000ZMutational constraints on RSV F and its neutralization by antibodieshttps://www.pharmaradar360.com/article/topographic-structure-and-function-of-locus-coeruleus-noradrenaline-neurons-36cc607a9bb0bd75PharmaRadar360en2026-09-16T00:00:00.000ZTopographic structure and function of locus coeruleus noradrenaline neuronshttps://www.pharmaradar360.com/article/targeted-genomic-integration-and-rearrangement-using-prime-assembly-bb5d887a8114b8b0PharmaRadar360en2026-09-16T00:00:00.000ZTargeted genomic integration and rearrangement using prime assemblyhttps://www.pharmaradar360.com/article/transcriptional-activation-of-plant-immunity-by-salicylic-acid-bb756098bf8d42d0PharmaRadar360en2026-09-16T00:00:00.000ZTranscriptional activation of plant immunity by salicylic acidhttps://www.pharmaradar360.com/article/mitochondrial-fission-factor-senses-and-governs-ferroptosis-c7d3f5a84d37b0c5PharmaRadar360en2026-09-16T00:00:00.000ZMitochondrial fission factor senses and governs ferroptosishttps://www.pharmaradar360.com/article/road-transport-of-trapped-antiprotons-6321250102761ec6PharmaRadar360en2026-09-16T00:00:00.000ZRoad transport of trapped antiprotonshttps://www.pharmaradar360.com/article/a-retinoic-acid-autoregulatory-loop-governing-prefrontal-motor-arealization-bff3419aeb23865aPharmaRadar360en2026-09-16T00:00:00.000ZA retinoic acid autoregulatory loop governing prefrontal–motor arealizationhttps://www.pharmaradar360.com/article/development-of-a-random-background-to-understand-ligand-optimization-beb0b7e790fb9f18PharmaRadar360en2026-09-16T00:00:00.000ZDevelopment of a random background to understand ligand optimizationhttps://www.pharmaradar360.com/article/continuous-wave-laser-absorption-spectroscopy-of-the-thorium-229-nucleus-5ea6739e71728e0dPharmaRadar360en2026-09-16T00:00:00.000ZContinuous-wave laser absorption spectroscopy of the thorium-229 nucleushttps://www.pharmaradar360.com/article/heterogeneous-photonic-integration-of-single-crystalline-nanomembranes-3c2e75d06c9c0e3aPharmaRadar360en2026-09-16T00:00:00.000ZHeterogeneous photonic integration of single-crystalline nanomembraneshttps://www.pharmaradar360.com/article/overmassive-black-holes-and-little-red-dots-naturally-form-in-simulations-8cac1eb342b3a544PharmaRadar360en2026-09-16T00:00:00.000ZOvermassive black holes and little red dots naturally form in simulationshttps://www.pharmaradar360.com/article/molecular-level-observation-of-the-self-assembly-of-a-virus-like-particle-5c1f81edd02d0106PharmaRadar360en2026-09-16T00:00:00.000ZMolecular-level observation of the self-assembly of a virus-like particlehttps://www.pharmaradar360.com/article/intratumor-delivery-of-a-novel-plasmid-combination-induces-high-levels-of-metast-79bbbc4147b72673PharmaRadar360en2026-09-16T00:00:00.000ZIntratumor delivery of a novel plasmid combination induces high levels of metastatic melanoma regressionhttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-a2d331d374f943b7PharmaRadar360en2026-09-16T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-bb15ffb56a868eb9PharmaRadar360en2026-09-16T00:00:00.000Znatco records %e2%82%b9794 4 crore consolidated revenue and %e2%82%b9206 5 crore of profit after tax for q1 fy27https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-ff3ca531de5730cePharmaRadar360en2026-09-16T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-07ffb382cc605b33PharmaRadar360en2026-09-16T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-ed6bb7eb9549f08fPharmaRadar360en2026-09-16T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-7cb7e32ad9131eb5PharmaRadar360en2026-09-16T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-742f3a5e16d17020PharmaRadar360en2026-09-16T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-8589d7753f9a150aPharmaRadar360en2026-09-16T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-65155282926117bbPharmaRadar360en2026-09-16T00:00:00.000Znatco pharma limited announces conclusion of us fda inspection at visakhapatnam andhra pradesh finished dosage formulations fdf unithttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-5fcd2c53d1117f58PharmaRadar360en2026-09-16T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-215330e6ed79ad0fPharmaRadar360en2026-09-16T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-b692b9f63b741656PharmaRadar360en2026-09-16T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-d8d78fac298637a5PharmaRadar360en2026-09-16T00:00:00.000Zinvestment of us 14 million in egenesis inc by natco pharma canada inc and natco pharma south africa proprietary limitedhttps://www.pharmaradar360.com/article/home-page-fd8df7af0ffe3d6cPharmaRadar360en2026-09-16T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/medicare-program-medicare-appeals-adjustment-to-the-amount-in-controversy-thresh-94915c4cbe3169f1PharmaRadar360en2026-09-16T00:00:00.000ZMedicare Program; Medicare Appeals; Adjustment to the Amount in Controversy Threshold Amounts for Calendar Year 2027https://www.pharmaradar360.com/article/medicare-program-public-meeting-for-new-revisions-to-the-healthcare-common-proce-0dc0a936f4b41fa5PharmaRadar360en2026-09-16T00:00:00.000ZMedicare Program; Public Meeting for New Revisions to the Healthcare Common Procedure Coding System (HCPCS) Level II Codinghttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-047468a183772e00PharmaRadar360en2026-09-16T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/opportunity-to-co-sponsor-events-with-the-office-of-research-integrity-e16a1d817cc2ee30PharmaRadar360en2026-09-16T00:00:00.000ZOpportunity To Co-Sponsor Events With the Office of Research Integrityhttps://www.pharmaradar360.com/article/government-owned-inventions-availability-for-licensing-8cbe3facb1cb1897PharmaRadar360en2026-09-16T00:00:00.000ZGovernment-Owned Inventions; Availability for Licensinghttps://www.pharmaradar360.com/article/center-for-scientific-review-amended-notice-of-meeting-e0e51e61efa854a9PharmaRadar360en2026-09-16T00:00:00.000ZCenter for Scientific Review; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/agency-information-collection-request-30-day-public-comment-request-f6ec9d29697e1d9ePharmaRadar360en2026-09-16T00:00:00.000ZAgency Information Collection Request; 30-Day Public Comment Requesthttps://www.pharmaradar360.com/article/order-under-sections-362-and-365-of-the-public-health-service-act-continuing-the-6789f7d61c90e383PharmaRadar360en2026-09-16T00:00:00.000ZOrder Under Sections 362 and 365 of the Public Health Service Act Continuing the Suspension of the Right To Introduce Certain Persons From Countries Where a Quarantinable Communicable Disease Existshttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-4931405acdc3599dPharmaRadar360en2026-09-16T00:00:00.000ZAgency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Biological Products: Reporting of Biological Product Deviations and Human Cells, Tissues, and Cellular and Tissue-Based Product Deviations in Manufacturinghttps://www.pharmaradar360.com/article/proposed-collection-60-day-comment-request-nih-intramural-reporting-of-research-9f712e6427b6b151PharmaRadar360en2026-09-16T00:00:00.000ZProposed Collection; 60-Day Comment Request; NIH Intramural Reporting of Research Misconduct (IRRM) Web Form (Office of the Director/Office of Intramural Research)https://www.pharmaradar360.com/article/microbiology-devices-panel-of-the-medical-devices-advisory-committee-notice-of-m-7f94431e812d15ddPharmaRadar360en2026-09-16T00:00:00.000ZMicrobiology Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Pathogen-Agnostic Sequencinghttps://www.pharmaradar360.com/article/wallenbergstiftelserna-beviljar-ai-stod-till-fyra-forskargrupper-vid-ki-269b0feada1a5a2bPharmaRadar360en2026-09-16T00:00:00.000ZWallenbergstiftelserna beviljar AI-stöd till fyra forskargrupper vid KIhttps://www.pharmaradar360.com/article/vill-bana-vag-for-nya-behandlingar-av-hudsjukdomar-123a8d0c9e3c54adPharmaRadar360en2026-09-16T00:00:00.000ZVill bana väg för nya behandlingar av hudsjukdomarhttps://www.pharmaradar360.com/article/okande-cancertrender-bland-unga-vuxna-ecaa398ef104a372PharmaRadar360en2026-09-16T00:00:00.000ZÖkande cancertrender bland unga vuxnahttps://www.pharmaradar360.com/article/ny-avhandling-utvecklar-statistiska-metoder-for-battre-brostcancervard-8eba6cbff21b3a27PharmaRadar360en2026-09-16T00:00:00.000ZNy avhandling utvecklar statistiska metoder för bättre bröstcancervårdhttps://www.pharmaradar360.com/article/ki-starker-positionerna-i-arets-shanghai-amnesrankning-484868928f5a1a0bPharmaRadar360en2026-09-16T00:00:00.000ZKI stärker positionerna i årets Shanghai-ämnesrankninghttps://www.pharmaradar360.com/article/clintec-forskare-inleder-samarbete-for-att-utveckla-nytt-naringsprotein-for-svar-059b8d3a1c617f61PharmaRadar360en2026-09-16T00:00:00.000ZCLINTEC-forskare inleder samarbete för att utveckla nytt näringsprotein för svårt sjuka patienterhttps://www.pharmaradar360.com/article/national-institute-on-aging-awards-21-1m-for-cleveland-alzheimer-s-disease-resea-7c0c0070442dcafaPharmaRadar360en2026-09-16T00:00:00.000ZNational Institute on Aging Awards $21.1M for Cleveland Alzheimer’s Disease Research Centerhttps://www.pharmaradar360.com/article/cleveland-clinic-s-world-class-care-now-available-to-more-bermuda-residents-56da421e905c6660PharmaRadar360en2026-09-16T00:00:00.000ZCleveland Clinic’s World-Class Care Now Available to More Bermuda Residentshttps://www.pharmaradar360.com/article/study-finds-why-young-adults-may-develop-early-fatty-liver-disease-6ea37405cd1da8d8PharmaRadar360en2026-09-16T00:00:00.000ZStudy Finds Why Young Adults May Develop Early Fatty Liver Diseasehttps://www.pharmaradar360.com/article/the-mask-of-delirium-uncovering-a-presumed-cardioembolic-stroke-through-comprehe-ef13b4747a34df72PharmaRadar360en2026-09-16T00:00:00.000ZThe Mask of Delirium: Uncovering a Presumed Cardioembolic Stroke Through Comprehensive Clinical Evaluationhttps://www.pharmaradar360.com/article/mitof-an-integrated-ai-framework-for-forecasting-and-structured-reporting-in-cli-92bbf44c143caa6ePharmaRadar360en2026-09-16T00:00:00.000ZMITOF: An Integrated AI Framework for Forecasting and Structured Reporting in Clinical Immunosuppressive Therapy Managementhttps://www.pharmaradar360.com/article/beyond-the-abstract-interpreting-research-and-avoiding-clinical-traps-in-emergin-7cbbccfd1ee4c5b8PharmaRadar360en2026-09-16T00:00:00.000ZBeyond the Abstract: Interpreting Research and Avoiding Clinical Traps in Emerging and Off-Label Treatmentshttps://www.pharmaradar360.com/article/lt-b-gt-anticoagulant-related-nephropathy-associated-with-vitamin-k-antagonists-81cedfa5bb50a11cPharmaRadar360en2026-09-16T00:00:00.000Z<b>Anticoagulant-Related Nephropathy Associated with Vitamin K Antagonists and Direct Oral Anticoagulants: Epidemiology, Pathophysiology, Clinical Features, and Outcomes</b>https://www.pharmaradar360.com/article/introductory-chapter-the-evolving-landscape-of-biomarkers-in-cancer-detection-an-ceb49675711378a1PharmaRadar360en2026-09-16T00:00:00.000ZIntroductory Chapter: The Evolving Landscape of Biomarkers in Cancer Detection and Clinical Translationhttps://www.pharmaradar360.com/article/evaluation-of-the-effect-of-aqueous-extract-of-azanza-garckeana-fruit-on-fertili-4a4cb3fe56758aa3PharmaRadar360en2026-09-16T00:00:00.000ZEvaluation of the Effect of Aqueous Extract of Azanza garckeana Fruit on Fertility Hormones in Alloxan Induced Diabetic Albino Wistar Ratshttps://www.pharmaradar360.com/article/clinical-characteristics-and-surgical-outcomes-of-retroperitoneal-unicentric-cas-afcd2297f84e5ad9PharmaRadar360en2026-09-16T00:00:00.000ZClinical Characteristics and Surgical Outcomes of Retroperitoneal Unicentric Castleman Disease: A Single-Center Retrospective Studyhttps://www.pharmaradar360.com/article/effects-of-transcutaneous-electrical-acupoint-stimulation-on-colonic-spasm-durin-360fb6c6fc59753aPharmaRadar360en2026-09-16T00:00:00.000ZEffects of transcutaneous electrical acupoint stimulation on colonic spasm during colonoscopy: A randomized controlled trialhttps://www.pharmaradar360.com/article/figure-2-from-nikolov-d-nikolov-g-kitova-l-kitov-s-kitova-m-f-mihaylova-aa-2026-4616545417902bdbPharmaRadar360en2026-09-16T00:00:00.000ZFigure 2 from: Nikolov D, Nikolov G, Kitova L, Kitov S, Kitova M-F, Mihaylova AA (2026) Rituximab therapy in severe PR3-ANCA pulmonary–renal syndrome: A clinical and pharmaceutical case report. Pharmacia 73: e201634. https://doi.org/10.3897/pharmacia.73.e201634https://www.pharmaradar360.com/article/review-of-aligner-materials-and-their-clinical-applications-a-literature-review-393d4d6ab5bd9c14PharmaRadar360en2026-09-16T00:00:00.000ZReview of aligner materials and their clinical applications: A literature reviewhttps://www.pharmaradar360.com/article/engineering-of-ohet72-nanocrystals-into-nanostructured-microparticles-for-pulmon-b1f7a2598f504136PharmaRadar360en2026-09-16T00:00:00.000ZEngineering of OHet72 Nanocrystals into Nanostructured Microparticles for Pulmonary Delivery of a Novel Antitubercular Drug Candidatehttps://www.pharmaradar360.com/article/chia-seed-allergy-emerging-clinical-evidence-molecular-allergens-and-the-unresol-facb4541734c3403PharmaRadar360en2026-09-16T00:00:00.000ZChia Seed Allergy: Emerging Clinical Evidence, Molecular Allergens, and the Unresolved Question of Cross-Reactivityhttps://www.pharmaradar360.com/article/perioperative-hydrogen-inhalation-and-postoperative-pain-after-endoscopic-discec-722474615b8d9e0dPharmaRadar360en2026-09-16T00:00:00.000ZPerioperative Hydrogen Inhalation and Postoperative Pain After Endoscopic Discectomy: A Pilot Non-Randomized Clinical Study with Exploratory Murine Datahttps://www.pharmaradar360.com/article/equivocal-dopamine-transporter-imaging-integrating-visual-assessment-quantificat-fc6783a086ee78abPharmaRadar360en2026-09-16T00:00:00.000ZEquivocal Dopamine Transporter Imaging: Integrating Visual Assessment, Quantification, and Clinical Follow-Uphttps://www.pharmaradar360.com/article/neural-interfaces-for-bidirectional-sensory-restoration-in-limb-prostheses-curre-5c6660fd982425f1PharmaRadar360en2026-09-16T00:00:00.000ZNeural Interfaces for Bidirectional Sensory Restoration in Limb Prostheses: Current Evidence and Clinical Translationhttps://www.pharmaradar360.com/article/acute-limb-ischemia-during-pregnancy-a-case-report-and-narrative-review-of-the-l-f51dd976cf886305PharmaRadar360en2026-09-16T00:00:00.000ZAcute Limb Ischemia During Pregnancy: A Case Report and Narrative Review of the Literaturehttps://www.pharmaradar360.com/article/effects-of-botulinum-toxin-injection-on-masticatory-muscle-activity-in-sleep-bru-302744fb35ec2609PharmaRadar360en2026-09-16T00:00:00.000ZEffects of Botulinum Toxin Injection on Masticatory Muscle Activity in Sleep Bruxism: A Systematic Review and Meta-Analysishttps://www.pharmaradar360.com/article/in-vivo-comparison-of-laser-fluorescence-near-infrared-transillumination-and-con-4347cb2b342715dbPharmaRadar360en2026-09-16T00:00:00.000ZIn Vivo Comparison of Laser Fluorescence, Near-Infrared Transillumination, and Conventional Methods for Approximal Caries Detectionhttps://www.pharmaradar360.com/article/aging-in-schizophrenia-clinical-biological-and-psychosocial-perspectives-3357f8913b674d08PharmaRadar360en2026-09-16T00:00:00.000ZAging in Schizophrenia: Clinical, Biological, and Psychosocial Perspectiveshttps://www.pharmaradar360.com/article/clinical-outcomes-in-pediatric-acute-lymphoblastic-leukemia-a-retrospective-coho-b454992a5aa3bec2PharmaRadar360en2026-09-16T00:00:00.000ZClinical outcomes in pediatric acute lymphoblastic leukemia: a retrospective cohort study from a tertiary center in Indonesiahttps://www.pharmaradar360.com/article/transcutaneous-auricular-vagus-nerve-stimulation-targets-the-brain-gut-axis-to-t-c7ed69eab8b988b5PharmaRadar360en2026-09-16T00:00:00.000ZTranscutaneous auricular vagus nerve stimulation targets the brain-gut axis to treat functional dyspepsia: a scoping review of clinical evidence and mechanistic researchhttps://www.pharmaradar360.com/article/mafld-is-linked-to-lower-hbv-dna-levels-in-chronic-hepatitis-b-clinical-and-tran-89e3837cbe2b6f2cPharmaRadar360en2026-09-16T00:00:00.000ZMAFLD is linked to lower HBV DNA levels in chronic hepatitis B: clinical and transcriptomic insightshttps://www.pharmaradar360.com/article/interpretable-machine-learning-models-using-early-dynamic-clinical-features-to-p-2f08580acd61747fPharmaRadar360en2026-09-16T00:00:00.000ZInterpretable machine learning models using early dynamic clinical features to predict early hemodynamic stabilization after vasopressor initiation in patients with septic shock: development in MIMIC-IV and external validation in eICUhttps://www.pharmaradar360.com/article/development-and-internal-validation-of-a-clinical-nomogram-for-identifying-lupus-8cf07557b9131fc2PharmaRadar360en2026-09-16T00:00:00.000ZDevelopment and internal validation of a clinical nomogram for identifying lupus nephritis in patients with systemic lupus erythematosushttps://www.pharmaradar360.com/article/roles-of-community-drug-distributors-in-health-and-development-activities-post-o-449965f56fbda972PharmaRadar360en2026-09-16T00:00:00.000ZRoles of community drug distributors in health and development activities post-onchocerciasis elimination in Ugandahttps://www.pharmaradar360.com/article/engineering-the-oxidative-myocardium-ros-responsive-biomaterials-for-precision-c-f850207104621730PharmaRadar360en2026-09-16T00:00:00.000ZEngineering the oxidative myocardium: ROS-responsive biomaterials for precision cardiovascular delivery in ischemia-reperfusion injury and post-infarction remodelinghttps://www.pharmaradar360.com/article/a-framework-of-microbial-genomic-database-for-clinical-metagenomic-pathogen-diag-45db2974831d7577PharmaRadar360en2026-09-16T00:00:00.000ZA framework of Microbial Genomic Database for clinical metagenomic pathogen diagnosis: development and multi-cohort evaluationhttps://www.pharmaradar360.com/article/clinical-outcomes-and-their-relationship-with-tigecycline-exposure-in-critically-fd1c7aa5123cab7ePharmaRadar360en2026-09-16T00:00:00.000ZClinical outcomes and their relationship with tigecycline exposure in critically ill patients with drug resistant infectionshttps://www.pharmaradar360.com/article/toward-standardized-continuous-glucose-monitoring-validation-lessons-from-the-si-d07f20738b0bc797PharmaRadar360en2026-09-16T00:00:00.000ZToward standardized continuous glucose monitoring validation: lessons from the Sinocare iCan i3 accuracy studyhttps://www.pharmaradar360.com/article/partial-clinical-remission-in-type-1-diabetes-pancreatic-cell-functional-reserve-6253910902309061PharmaRadar360en2026-09-16T00:00:00.000ZPARTIAL CLINICAL REMISSION IN TYPE 1 DIABETES: PANCREATIC Β - CELL FUNCTIONAL RESERVE, PRE-DICTORS, AND CLINICAL SIGNIFICANCE (A NARRA-TIVE REVIEW)https://www.pharmaradar360.com/article/using-artificial-intelligence-to-build-the-radiology-clinical-trial-office-of-th-b61603ea2320a841PharmaRadar360en2026-09-16T00:00:00.000ZUsing Artificial Intelligence to Build the Radiology Clinical Trial Office of the Future: Functional, Fast, and Cost-Effectivehttps://www.pharmaradar360.com/article/the-universal-biocode-framework-2-0-a-philosophical-numerical-integration-of-mul-66d5897507ba8e2ePharmaRadar360en2026-09-16T00:00:00.000ZThe Universal BioCode Framework 2.0: A Philosophical-Numerical Integration of Multi-Omic Data, Spatial Technologies, and Clinical Outcomes for Precision Medicinehttps://www.pharmaradar360.com/article/three-month-clinical-outcomes-and-exploratory-gait-changes-after-intra-articular-4792c080c51d3b2dPharmaRadar360en2026-09-16T00:00:00.000ZThree-Month Clinical Outcomes and Exploratory Gait Changes After Intra- Articular Platelet-Rich Plasma for Mild-to-Moderate Knee Osteoarthritis: A Prospective Single-Arm Studyhttps://www.pharmaradar360.com/article/clinical-outcomes-of-short-versus-long-course-antibiotic-therapy-in-pseudomonas-8d14d9e4f063d84bPharmaRadar360en2026-09-16T00:00:00.000ZClinical Outcomes of Short- Versus Long-Course Antibiotic Therapy in Pseudomonas aeruginosa-Positive Mild-to-Moderate Bronchiectasis Stratified by Day-7 Sputum Bacterial Loadhttps://www.pharmaradar360.com/article/the-effectiveness-of-bcw-based-family-participated-digital-assisted-intervention-f1f13e21ba0263eaPharmaRadar360en2026-09-16T00:00:00.000ZThe effectiveness of BCW-based family-participated digital-assisted intervention on health belief, health literacy and social support in old individuals with high-risk of colorectal cancer: A single- blinded randomized controlled trialhttps://www.pharmaradar360.com/article/drug-interaction-with-inhibitors-prediction-of-exposure-of-drugs-following-drug-1b93a2c92477e7f9PharmaRadar360en2026-09-16T00:00:00.000ZDrug Interaction with Inhibitors: Prediction of Exposure of Drugs Following Drug-Inhibitor Interaction Based on Molecular Weight Ratio